🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million instances annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization represents a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Global Access

Based on results detailed in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to make available and distribute the drug in numerous regions with limited resources.

Medical professionals treating patients have shared optimism. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for public health efforts. This is viewed as essential to reduce the burden of the infection for people and to prevent the spread of untreatable gonorrhoea globally.